Bio-Techne Corp
$ 57.87
0.47%
25 Feb - close price
- Market Cap 9,053,952,000 USD
- Current Price $ 57.87
- High / Low $ 58.24 / 56.88
- Stock P/E 109.19
- Book Value 12.90
- EPS 0.53
- Next Earning Report 2026-05-06
- Dividend Per Share $0.32
- Dividend Yield 0.56 %
- Next Dividend Date 2026-02-27
- ROA 0.07 %
- ROE 0.04 %
- 52 Week High 72.06
- 52 Week Low 45.74
About
Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services for the global clinical diagnostic and research markets. The company is headquartered in Minneapolis, Minnesota.
Analyst Target Price
$75.25
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-04 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-05 | 2024-10-30 | 2024-08-07 | 2024-05-01 | 2024-02-01 | 2023-10-31 | 2023-08-08 | 2023-05-03 |
| Reported EPS | 0.46 | 0.42 | 0.53 | 0.56 | 0.42 | 0.42 | 0.49 | 0.48 | 0.4 | 0.41 | 0.55 | 0.53 |
| Estimated EPS | 0.43 | 0.43 | 0.5 | 0.51 | 0.39 | 0.38 | 0.49 | 0.45 | 0.41 | 0.44 | 0.55 | 0.53 |
| Surprise | 0.03 | -0.01 | 0.03 | 0.05 | 0.03 | 0.04 | 0 | 0.03 | -0.01 | -0.03 | 0 | 0 |
| Surprise Percentage | 6.9767% | -2.3256% | 6% | 9.8039% | 7.6923% | 10.5263% | 0% | 6.6667% | -2.439% | -6.8182% | 0% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.5411 |
| Currency | USD |
Previous Dividend Records
| Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Jan 1970 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-02-27 | 2025-11-28 | 2025-08-29 | 2025-05-30 | 2025-02-28 | None | 2024-11-22 | 2024-08-30 | 2024-05-24 | 2024-02-26 |
| Amount | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 |
Next Dividend Records
| Dividend per share (year): | $0.32 |
| Dividend Yield | 0.56% |
| Next Dividend Date | 2026-02-27 |
| Ex-Dividend Date | 2026-02-13 |
Recent News: TECH
2026-02-24 21:30:00
Bio-Techne Corp. (TECH) stock significantly outperformed its competitors on a strong trading day, with shares advancing 5.19% to $57.60. This rise ended a three-day losing streak for the company. The broader market also saw positive movement, with the S&P 500 Index and the Dow Jones Industrial Average both posting gains.
2026-02-24 19:51:51
Bio-Techne Corporation (NASDAQ:TECH) is highlighted as one of the top life sciences stocks by hedge funds, with analysts reaffirming their ratings and raising price targets. Despite expectations of flat mid-year growth and an unchanged forecast for the coming year, analysts see promise in the company's FY27 organic growth projections. Bio-Techne develops and markets life sciences instruments, reagents, diagnostics, and related services for various markets.
2026-02-24 19:51:32
Bio-Techne Corporation (TECH) is viewed positively by analysts for its FY27 organic growth projections, despite some near-term flatness. Stifel Nicolaus and Evercore ISI analysts both reiterated their ratings, increasing price targets and noting promising long-term prospects for the life sciences company. Bio-Techne develops and markets various life sciences instruments, reagents, and diagnostic products for several markets.
2026-02-24 14:28:00
Bio-Techne Corporation (TECH) is viewed as a promising life sciences stock by hedge funds, with analysts reaffirming their ratings and raising price targets. Despite an anticipated flat mid-year growth and a downward adjustment for the next quarter, analysts are optimistic about the company's FY27 organic growth projections. Bio-Techne develops and sells life sciences instruments and related services for various markets.
2026-02-24 14:28:00
Bio-Techne Corporation (TECH) is highlighted for its attractive FY27 organic growth projections, despite expectations of flat mid-year growth and a potential downward adjustment for the next quarter. Analysts Daniel Arias from Stifel Nicolaus and Daniel Markowitz from Evercore ISI both re-affirmed ratings and raised price targets for the stock, citing optimism for the company's long-term outlook. Bio-Techne develops and markets various life sciences instruments and services for clinical research, diagnostics, gene therapy, and bioprocessing markets.
2026-02-24 11:51:18
Bio-Techne Corporation announced its participation in two upcoming investor conferences: the TD Cowen 46th Annual Health Care Conference on March 3, 2026, and the Leerink Partners Global Healthcare Conference on March 10, 2026. Live webcasts of these presentations will be available on the company's Investor Relations website. Bio-Techne, a global life sciences company, provides innovative tools and reagents for research and clinical diagnostics.
